Skip to main content
. 2022 May 31;10:884349. doi: 10.3389/fpubh.2022.884349

Table 2.

Demographic and clinicopathological characteristics of pancreatic cancer patients with lung metastases in training cohort.

Characteristic Without LM cohort (n = 12,787)
No. of patients %
With LM cohort (n = 561)
No. of patients %
P-value
Age 0.013#
Median 67 68
Range 59–75 60–76.5
Race 0.125
White 10,286 80.4 434 77.4
Black 1,394 10.9 76 13.5
Other 1,107 8.7 51 9.1
Sex 0.087
Female 6,138 48.0 290 51.7
Male 6,649 52.0 271 48.3
Histological subtype <0.001
Adenocarcinoma 6,456 50.5 398 70.9
Infiltrating duct carcinoma 3,484 27.2 70 12.5
Neuroendocrine carcinoma 981 7.7 27 4.8
Other 1,866 14.6 66 11.8
Grade <0.001
Well-differentiated: I 2,794 21.9 55 9.8
Moderately differentiated: II 5,299 41.4 210 37.4
Poorly differentiated: III 4,438 34.7 270 48.1
Undifferentiated; anaplastic: IV 256 2.0 26 4.6
Primary site <0.001
Head of pancreas 7,551 59.1 215 38.3
Body of pancreas 1,518 11.9 107 19.1
Tail of pancreas 2,098 16.4 136 24.2
Pancreatic duct 61 0.5 4 0.7
Other specified parts of pancreas 218 1.7 9 1.6
Overlapping lesion of pancreas 814 6.4 54 9.6
Pancreas, NOS 527 4.1 36 6.4
AJCC T stage <0.001
T1 1,246 9.7 18 3.2
T2 2,418 18.9 174 31.0
T3 7,511 58.7 208 37.1
T4 1,612 12.6 161 28.7
AJCC N stage 0.007
N0 6,235 48.8 241 43.0
N1 6,552 51.2 320 57.0
Surgery <0.001
No 4,232 33.1 517 92.2
Yes 8,555 66.9 44 7.8
Radiotherapy <0.001
No 9,952 77.8 510 90.9
Yes 2,835 22.2 51 9.1
Chemotherapy 0.340
No 5,457 42.7 228 40.6
Yes 7,330 57.3 333 59.4
Tumor size <0.001#
Median 35 45
Range 25–45 33–60
Brain metastasis <0.001
No 12,779 99.9 553 98.6
Yes 8 0.1 8 1.4
Bone metastasis <0.001
No 12,678 99.1 504 89.8
Yes 109 0.9 57 10.2
Liver metastasis <0.001
No 10,831 84.7 251 44.7
Yes 1,956 15.3 310 55.3

# Mann-Whitney U-test.